Debris and immunoglobulin accumulation due to inappropriate cell elimination systems in aging trigger the innate immune system activation leading to persist inflammation. Glycosylation represents the most frequent post-translational modification of proteins. Protein-linked sugar chains play a variety of specific roles in the “fine-tuning” of interactions between cells and between molecules (11, 12). High-throughput analysis of the N-glycome, i.e., the sugar chains N-linked to asparagine, revealed new candidate biomarkers of natural aging, such as N-glycans devoid of galactose residues on their branches, in a variety of human studies (13–15) comparing healthy elderly people, centenarians, and their offspring, as well as in experimental animal models (16–18), such as the calorie-restricted mice model. These agalactosylated biantennary structures mainly decorate Asn297 of the Fc portion of IgG (IgG-G0) and are present in patients affected by progeria syndromes as well as a several autoimmune/inflammatory diseases. IgG-G0 exerts a pro-inflammatory effect through various mechanisms, including the lectin pathway of complement, binding to Fcγ receptors and formation of autoantibody aggregates. Similarly, the age-related accumulation of IgG-G0 activating the immune system can contribute to inflammaging. On the other hand, among the complex determinants of aging, mitochondrial dysfunction has attracted attention for some time. The consequences of age-related failing mitochondrial quality control include the release of mitochondria-derived damage-associated molecular patterns (DAMPs). Mitochondrial DAMPs, especially cell-free circulating mitochondrial DNA, have recently become the subject of intensive research because of their possible involvement in conditions associated with inflammation, such as aging and degenerative diseases (19, 20). Through their bacterial ancestry, these molecules contribute to increasing an inflammatory response by interacting with receptors similar to those involved in pathogen-associated responses.

The barrier of the oral and gut mucosa against bacterial invasion deteriorates with age. Periodontal disease has also demonstrated to cause chronic low-grade inflammation (12). The gut microbiota of elderly people displays decreased diversity (21, 22). The abundance of anti-inflammatory microbiota, such as members of Clostridium cluster XIVa, Bifidobacterium spp., and F. prausnitzii are diminished in aged individuals (23). Toward R et al. demonstrated supportive data that the level of Bifidobacterium is inversely correlated with serum levels of inflammatory cytokines, such as TNF-α and IL-1β. Conversely, inflammatory and pathogenic microbiota, including Streptococcus spp., Staphylococcus spp., Enterococcus spp. and Enterobacter spp., are increased with age (23). Changes in the gut microbiota diversity in aged people might increase susceptibility to infectious agents by pathobionts colonization. Unique stool microbiota profiles were evident between healthy “community-dwelling elderly” and subjects with “residential long-term care” (24). These differences might be due to the disparate consumption of food in various groups, suggesting a new therapeutic target for prolonged healthy life years.

Cellular senescence is defined as irreversible cell cycle arrest driven by a variety of mechanisms, including telomere shortening, genotoxic stress, mitogen stimuli, and inflammatory cytokines, that result in the activation of the p53 tumor suppressor and/or the cyclin-dependent kinase inhibitor p16 (25). It is evident that the number of senescent cells in several organs increases with age; these cells secrete multiple inflammatory cytokines, generating low-grade inflammation. This phenotype of senescent cells is termed the senescence-associated secretory phenotype or SASP, which recently has been proposed as the main origin of inflammaging in both aging and age-related diseases such as atherosclerosis, cancer, and diabetes (26–28). Increasing evidence has suggested that the clearance of senescent cells in animal models attenuates the progression of age-related disorders, including atherosclerosis and osteoarthritis (29–31). These data strongly support the hypothesis that senescent cell clearance, reprogramming of senescent cells, and the modulation of pro-inflammatory pathways related to the acquisition of SASP might be pursued as potential anti-aging strategies for combating age-related diseases and expanding the health span of humans.

“Immunosenescence”, which is the age-related dysregulation of an innate immune system, is characterized by persistent inflammatory responses (32). Immunosenescence increases the susceptibility to malignancy, autoimmunity, and infections; decreases the response to vaccinations; and impairs wound healing (33, 34). Conversely, chronic inflammatory disease can accelerate the “immunosenescence” process. The mechanisms that underlie this persistent aging-associated basal inflammation remain incompletely understood but seem to involve changes in the numbers and functions of innate immune cells. Changes in the expression of pattern recognition receptors (PRRs), activation of PRRs by endogenous ligands associated with cellular damage, and unusual downstream signaling events of PRRs activation have been implicated to induce chronic cytokine secretion. Thus, together with cell senescence, dysregulation of immunological imprinting mediated by trained innate immunity might also contribute to persistent low-grade inflammation that occurs even after the initial stimulus has been removed.

Increased coagulation and fibrinolysis activity in the elderly has recently been implicated in enhanced inflammation through the protease-activated receptor, PAR (35–37) leading to age-related diseases such as atherosclerosis and lung fibrosis (38). The plasma concentrations of coagulation factor V, VII, VIII, and IX, have been reported to increase in healthy humans in conjunction with the physiological processes of aging (39, 40). In addition, fibrinogen (coagulation factor I) levels, a primary risk factor for thrombotic disorders proved in several clinical studies, has been shown to increase with advancing age. Additionally, we have recently identified that coagulation factor X is locally synthesized at high levels in human atherosclerotic plaques, specifically in endothelial cells, smooth muscle cells, and inflammatory cells (41). Thus, based on these observations, increased levels of plasma and local coagulation factors during physiological aging might account for the higher cardiovascular risk observed in the elderly. Additionally, a clinical trial, ATLAS ACS 2–TIMI, 51 investigators showed that the direct coagulation factor Xa inhibitor, rivaroxaban, reduced the risk of the composite endpoint of death from cardiovascular causes, myocardial infarction, and stroke in patients with a recent acute coronary syndrome event (42). Although the mechanism has not been elucidated, activation of the coagulation cascade following fibrinogen activation may increase thrombosis, and elevated levels of coagulation factor Xa and thrombin could enhance the inflammatory response through PAR-1/2, in addition to its roles in coagulation and the fibrinolysis system (43). Interestingly, PAR-1/2 signaling induced by coagulation factor Xa (FXa) and the fibrinolytic factor plasmin has been shown to increase insulin-like growth factor binding protein-5 (IGFBP-5) expression (37, 41, 44, 45), which plays decisive roles in cell senescence and inflammation. Kojima et al. demonstrated that IGFBP-5, a downstream mediator of signal transducer and activator of transcription 3 (STAT3), regulates interleukin-6 (IL-6)-induced reactive oxygen species production, subsequent DNA damage response, and senescence of fibroblast cells (46). As shown in the study by Yasuoka et al., IGFBP-5 induces a fibrotic phenotype by activating MAPK signaling and nuclear EGR-1 translocation that interacts with IGFBP-5 and promotes fibrotic and inflammatory gene transcription (47). Consistent with previous reports, our recent study demonstrated that FXa stimulation of smooth muscle cells, endothelial cells, and endothelial progenitor cells enhances cellular senescence through the early growth response-1 (EGR-1)-IGFBP-5-p53 pathway (37). These data imply that inflammaging, hyper-coagulability, and cell senescence might share a common pathway that is regulated by IGFBP-5 (Figure 2). Intriguingly, our recent experiment showed that the FXa- and IGFBP-5-positive areas were similarly distributed within human atherosclerotic plaques (41). These finding strongly suggest that locally produced coagulation factor Xa in atherosclerotic plaques might induce IGFBP-5 expression, enhancing cellular senescence with SASP, although the involvement of thrombin in this process is undeniable (48).